Table of Contents
Jefferies Global Healthcare Conference in London
Date: November 17-20, 2025
To view the webcast, please click here.
Related
Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results
✨ Onyx Summary Belite Bio announced it will host a webcast on March 2, 2026 at 4:30 p.m. ET to discuss fourth-quarter and full-year 2025 financial results and provide a business update. A live webcast and a replay (available for about 90 days) will be accessible via the company’
Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation for AFTX-201 in BAG3-Associated Dilated Cardiomyopathy (DCM)
✨ Onyx Summary Affinia Therapeutics said the European Medicines Agency has granted Orphan Drug designation to AFTX-201, its investigational AAV gene therapy for BAG3-associated dilated cardiomyopathy, following the FDA’s acceptance of its IND. The designation adds regulatory incentives and market-exclusivity potential in the EU as Affinia advances a one-time intravenous
Verily launches free version of its Pre Exchange and Workbench solutions, powering precision health AI and discovery
✨ Onyx Summary Verily launched self-serve access to its Pre precision health platform, adding a free Standard tier that lets individual researchers use Exchange and the Workbench secure analysis environment to discover and analyze select biomedical datasets under a data use agreement. The company also outlined additional data sources coming to
Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors
✨ Onyx Summary Cellares and the University of Wisconsin School of Medicine and Public Health expanded their partnership to move UW’s CRISPR-edited GD2 CAR-T program for solid tumors into clinical manufacturing and support an FDA IND submission, with Cellares providing automated manufacturing (Cell Shuttle) and automated QC (Cell Q) plus
Comments